In malignant tumors, e.g., breast, intestinal, ovarian, prostate, liver, and nasopharyngeal cancers, MAPK/ERK pathway inhibitors are used to slow down disease progression [14]. The gene discussed is MAPK1; the disease is nasopharyngeal carcinoma.